---
document_datetime: 2023-09-21 21:43:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/kogenate-bayer-epar-procedural-steps-taken-authorisation_en.pdf
document_name: kogenate-bayer-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3738989
conversion_datetime: 2025-12-24 22:36:35.751197
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  Company  Bayer  AG,  Germany  submitted  on  5  February  1999  an  application  for  Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for KOGENATE Bayer, in accordance with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993, as amended.

The Rapporteur and Co-Rapporteur appointed by the CPMP  were: Rapporteur: Dr. Manfred Haase Co-Rapporteur: Prof. Bo Odlind/Dr Tomas Salmonson Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 26 February 1999. · The Rapporteur's first assessment report was circulated to all CPMP Members on 13 May 1999. The Co-Rapporteur's first  assessment  report  was  circulated  to  all  CPMP  Members  on  7  May 1999. · During the meeting on 22-23 June 1999 the CPMP agreed on the consolidated list of questions to be sent to the Company. The final consolidated list of questions was sent to the Company on 24 June 1999. · The  Company  submitted  the  responses  to  the  CPMP  consolidated  list  of  questions  on  22 October 1999. · The report of the testing of samples by the Paul Ehrlich Institut was issued on 26 August 1999. · The Rapporteur and Co-Rapporteur circulated the response assessment report on the company's responses to the list of questions to all CPMP Members on 17 December 1999. · During  the  CPMP  meeting  on  18-20  January  2000,  the  CPMP  adopted  a  list  of  unresolved issues that was sent to the Company on 20 January 2000. · The Applicant provided written information on these unresolved issues on 24 February 2000. The joint assessment reports on this written information were circulated on 3 March 2000 for Part II and 13 March 2000 for Part IV. · A clarification  meeting on the outstanding issues took place during the BWP meeting on 7-8 March 2000. · During the meeting on 14-16 March 2000 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to KOGENATE Bayer on 16 March 2000. · The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 4 August 2000. Medicinal product no longer authorised